HALO
Halozyme Therapeutics, Inc. (HALO) Stock Valuation
Review Halozyme Therapeutics, Inc. (HALO) valuation with company data, supporting context and links to related investor research.
Research record updated: . Individual measures may refer to different reporting periods.
- Price to earnings
- 33.89
- Price to book
- 162.13
- BTI fair market cap
- $13.13B
- Premium or discount
- -0.97%
- Market cap
- $13.00B
Halozyme Therapeutics, Inc. (HALO) Stock Valuation research
The Halozyme Therapeutics, Inc. valuation page presents the available multiples, profitability measures and BTI fair-value context for HALO. Valuation should be compared with the company's growth, margins, balance sheet and relevant peers rather than judged by one multiple.
A premium may reflect stronger expected growth or quality, while a discount can reflect risk or weak expectations. Neither condition alone establishes that a stock is attractive or unattractive.
BTI fair value is a model estimate, not a quoted market price. The underlying assumptions and valuation date must be checked in the valuation tool before using the premium or discount. A missing multiple must not be interpreted as zero cost or zero risk.